The human immunoglobulin (pH4) for intravenous injection market is experiencing significant growth due to the rising prevalence of various immune disorders, such as chronic inflammatory demyelinating polyneuropathy, primary immunodeficiency diseases, and others. Immunoglobulin plays a vital role in treating these disorders by replacing antibodies and boosting the immune system. Some other key advantages of human immunoglobulin treatment are high efficacy and safety with limited side effects. The constant technological advancements and product launches are also boosting the demand for intravenous immunoglobulin therapy.
The Global Human Immunoglobulin (Ph4) For Intravenous Injection Market Is Estimated To Be Valued At US$ 78.38 Bn In 2024 And Is Expected To Exhibit A CAGR Of 12.% Over The Forecast Period 2024 To 2031
Key Takeaways
Key players operating in the Human Immunoglobulin (pH4) for Intravenous Injection are Takeda Pharmaceutical Company Limited, Baxter, CSL, Bayer AG, Grifols, S.A, Octapharma Brasil Ltda, Shanghai RAAS Blood Products Co Ltd, Hualan Biological Engineering, Inc, Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc), China Resources Boya Bio-pharmaceutical Group Co Ltd, ADMA Biologics, Inc, Sinopharm Group Co. Ltd. The increasing prevalence of immune disorders and growing awareness regarding immunoglobulin therapy has boosted the product demand significantly. Technological advancements including new fractionation methods and improved production efficiency have made the treatment more affordable and accessible to patients.
Market Trends
One of the key trends witnessed in the Human Immunoglobulin (pH4) for Intravenous Injection Market Demand is the growing preference for subcutaneous immunoglobulin over intravenous route of administration due to better tolerability and convenience of self-administration. Product innovations including development of high-dose formulations, extended half-life variants are also gaining traction. Furthermore, the market players are engaged in strategic collaborations and new product launches to strengthen their product portfolios and market position.
Market Opportunities
The untapped emerging economies represent significant growth opportunities owing to growing healthcare infrastructure and increasing healthcare spending. The development of new recombinant and monoclonal antibody-based immunotherapies also presents new opportunities. Additionally, expanding indications of intravenous immunoglobulins for other immune disorders will further propel the market growth in the coming years.
The COVID-19 pandemic has significantly impacted the growth of the Human
The Human Immunoglobulin (pH4) for Intravenous Injection Market Size and Trends phases of the pandemic, the supply chains were disrupted due to nationwide lockdowns imposed by various governments globally. This led to shortage of raw materials required for manufacturing Human Immunoglobulin. Several manufacturing plants had to halt their operations temporarily. The demand for Human Immunoglobulin also witnessed a surge initially due to its off-label use for treatment of COVID-19 patients with severe symptoms. However, as more treatments became available for COVID-19, the additional demand lowered. Nevertheless, the fear of coronavirus infection among immunocompromised patient population increased the overall demand for immunoglobulins throughout the forecast period.
Even though manufacturing and supply chain issues hampered market growth initially, companies are now well prepared to meet the demand through improved production planning, alternative sourcing, and inventory management. Technology advancements are also helping to enhance manufacturing processes and maximize yields. The recovery in demand post subsequent waves indicates strong market resiliency. Going forward, market players need to focus on expanding production capacities, establishing strategic partnerships for reliable supply, investing in R&D for new formulations, and creating awareness about effective treatment protocols.
In terms of value, North America dominates the global Human Immunoglobulin (pH4) for Intravenous Injection market. The region accounts for more than 40% of the total market value owing to developed healthcare infrastructure, presence of major players, and high acceptance of immunoglobulin therapy. Europe is the second largest regional market supported by growing intravenous immunoglobulin demand among autoimmune patients. Asia Pacific is recognized as the fastest growing region due to increasing healthcare spending, sizable patient populations, and improving access to immunoglobulin therapy in various countries.
The Human Immunoglobulin (pH4) for Intravenous Injection market in China accounts for over 25% of the total Asia Pacific market value and is recognized as the fastest growing regional market globally. Factors such as favorable government initiatives to strengthen domestic production capacity, presence of leading domestic players, growing immunodeficiency disorder prevalence, rising healthcare investments, and gradual acceptance of intravenous immunoglobulin therapy are fueling strong market growth in China. The market is projected to expand at a CAGR of over 15% during the forecast period on back of continued efforts by Chinese companies to enhance production volumes through capacity expansion and technology advancements.
Get More Insights: Human Immunoglobulin (pH4) for Intravenous Injection Market
For More Insights Discover the Report In language that Resonates with you
About Author:
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137)